Phantoms and Pharmaceuticals

The markets, as one observes, are afflicted with a peculiar fever. A trembling, a twitching, a desperate grasping for…something. In such times, one ought to seek refuge not in the fleeting illusions of speculative gain, but in the solid, if somewhat melancholy, foundations of established enterprise. The small caps, those eager, fluttering moths, promise much, yet are consumed too readily by the harsh realities of circumstance. A most undignified end, wouldn’t you agree?

And so, we turn our attention to Amarin, a name that whispers of ambition, yet delivers…well, a diminishing return, primarily. A curious case, indeed. One might even suspect a mischievous imp residing within their accounts, subtly diverting profits into a bottomless cup of tea. Instead, let us consider Novartis, a behemoth, yes, but one built upon the sturdy bones of actual, sustained earnings. A creature of habit, if you will, and habit, in these turbulent times, is a virtue.

The Fading Echo of Vascepa

Amarin’s shares have, for a fleeting moment, enjoyed a modest ascent, a brief dance with prosperity. But alas, the music has begun to fade. Their sole offering, Vascepa, a remedy for the palpitations of the modern age, is now haunted by the specter of generic competition. The generics, those tireless replicators, swarm like locusts, devouring the profits that once sustained Amarin’s modest existence. Revenue, in the last fiscal year, descended by 6.5%, a slow, mournful decline. It is as if the very lifeblood of the company is draining away.

They attempt, of course, to staunch the flow. Cost-cutting measures are enacted, a reduction in workforce…a necessary, if regrettable, pruning of the branches. They claim a net loss per share that is, comparatively, less catastrophic. But this is mere accounting, a rearranging of the deck chairs on a vessel that is, undeniably, taking on water. A clever illusion, perhaps, but one that will not long withstand the scrutiny of the unforgiving sea.

There is a legal skirmish, a battle waged with briefs and depositions, against Hikma Pharmaceuticals. A claim of patent infringement, a desperate attempt to reclaim lost territory. The case has ascended to the Supreme Court, a labyrinthine bureaucracy where justice moves at the pace of a particularly lethargic snail. Should Amarin prevail, a temporary reprieve might be granted. But even victory, in this instance, would be akin to applying a bandage to a gaping wound.

They have forged an alliance with Recordati Industria Chimica e Farmaceutica, a transfer of commercialization responsibilities, a shifting of risk. An upfront payment of $25 million, a mere pittance in the grand scheme of things. They hope to earn up to $150 million more, based on milestones achieved. A clever maneuver, perhaps, but one that merely delays the inevitable. It is like selling one’s coat in the midst of winter, hoping for a sudden, unexpected thaw.

These efforts are…commendable, in a tragically futile sort of way. But Amarin remains a precarious entity, dependent on a single, off-patent product, with no pipeline of future remedies. A phantom, clinging to the edge of existence. One should observe from a safe distance, perhaps, and offer a silent prayer for its continued, if improbable, survival.

The Solid Ground of Established Order

Novartis, in contrast, is a different beast altogether. A vast, sprawling empire of pharmaceuticals, with a product lineup that extends across a multitude of therapeutic areas. Consistent revenue, sustained earnings, a predictable rhythm of growth. In the last fiscal year, sales reached $54.5 billion, an increase of 8%. Earnings per share rose by 15%. A veritable fortress of financial stability.

Even when confronted with the loss of patent exclusivity for key products – Entresto, a remedy for the failing heart – Novartis remains resilient. Its extensive portfolio provides a buffer against adversity. It can absorb losses, adapt to changing circumstances, and continue to generate profits. A creature of habit, yes, but a habit of enduring success.

And then there is the pipeline, a veritable cornucopia of potential remedies. Dozens of clinical trials, a constant stream of innovation. New products are approved, existing ones are expanded. The loss of Entresto’s patent is merely a temporary setback. Fabhalta, a remedy for a pair of rare disorders, generated revenue of $505 million in the last fiscal year, an increase of 291%. A testament to the power of relentless innovation.

Novartis may not capture the headlines like some of its more flamboyant competitors, those chasing the fleeting mirage of the weight-loss market. But it is a solid, dependable enterprise, with a robust underlying business. Its shares have soared by 59% over the last 12 months, and it is poised for continued growth. It also offers a generous dividend, a reward for patient investors. For all these reasons, Novartis is a far more sensible investment than Amarin. A beacon of stability in a world consumed by chaos.

2026-03-03 17:32

The Fading Echo of Vascepa

The Solid Ground of Established Order

Read More